Table 5. The association results of SNPs in ADD3 to different subclinical features.
| Subphenotype | Comparison | Major risk haplotype | Replicated SNPs | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| T-G-G | rs17095355 | rs2501577 | ||||||||
| F_A | F_U | P | F_A | F_U | P | F_A | F_U | P | ||
| CBA/non-CBA | 44 CBA compared with 1473 controls | 0.45 | 0.39 | 0.23 | 0.46 | 0.42 | 0.41 | 0.48 | 0.43 | 0.34 |
| 462 non-CBA compared withs 1473 controls | 0.47 | 0.39 | 2.41E-05 | 0.49 | 0.42 | 2.19E-04 | 0.49 | 0.43 | 6.33E-04 | |
| Gender | 214 females compared with 506 controls | 0.48 | 0.38 | 9.10E-04 | 0.50 | 0.41 | 2.78E-03 | 0.52 | 0.42 | 1.41E-03 |
| 292 males compared with 967 controls | 0.48 | 0.46 | 0.59 | 0.48 | 0.42 | 0.017 | 0.47 | 0.43 | 0.064 | |
P, the patient‐only linear regression test between subclinical groups including CBA/non-CBA patients, female and male patients; F_A/F_U indicates risk allele frequency of the SNP in patients with/without the clinical features.